VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
178.69
+0.75 (+0.42%)
As of 11:37AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close177.94
Open178.52
Bid178.57 x 800
Ask178.66 x 800
Day's Range177.00 - 180.11
52 Week Range145.37 - 195.81
Volume306,836
Avg. Volume1,245,612
Market Cap45.766B
Beta (3Y Monthly)1.22
PE Ratio (TTM)21.53
EPS (TTM)8.30
Earnings DateJul 23, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est208.86
Trade prices are not sourced from all markets
  • InvestorPlace5 days ago

    7 Top-Rated Biotech Stocks to Invest In Today

    Tech stocks are tumbling around like they're in a washing machine. Between the trade wars and varying economic numbers, chip stock have been all over the place. While the Nasdaq Biotech Index (INDEXNASDAQ:NBI) is up 7% year to date, it was a bumpy ride through the latter part of 2018.This year, the broad biotech sector has been buffeted along with other broad market indicators, considering that the weaker-than-expected U.S. economy and the continued trade war with China have slapped a question mark over that growth market.Also, U.S. healthcare seems to be frozen in place for now, so "silver bullet" medicines aren't getting the attention they deserve. And the administrations crackdown on funding and researchers at the National Institutes of Health are also challenging since most major drug discoveries start at NIH and are then pulled into R&D efforts at biotech and pharma companies.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Quality Cheap Stocks to Buy With $10 But following are seven healthy biotech stocks to buy now. They get top scores in my Portfolio Grader for their fundamentals, earnings and momentum. These seven biotechs are both big and small, the one thing they have in common is growth now and in their future. Biotech Stocks to Buy: Repligen (RGEN)Repligen Corp (NASDAQ:RGEN) has had quite a good year, up 65% in the past 12 months, and 42% year to date. If a biotech or a Big Pharma are the bakeries that sell the finished goods, RGEN is the company that sells the ingredients and tools to the bakeries.It has three divisions: Chromotography (the separation of a mixture by passing it through a suspension), Filtration and OEM Products (usually proteins used for purification and cell growth products).These "ingredients" are certainly more complex than they are for a bakery, but they're just as fundamental to building drugs and manufacturing them with quality and consistency on a large scale.With a $3.6 billion market cap, RGEN is a good sized player with exposure across the industry, so it's a leveraged played on the fundamental growth in the biotech and pharmaceutical sector. And that's a solid investment moving forward. Vertex Pharma (VRTX)Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a big-cap pharmaceutical firm based out Boston, MA. It currently has three approved drugs to treat cystic fibrosis (CF) and has a number of drugs in the pipeline to treat other auto-immune diseases.Earlier this month it moved into the genetic therapy side of the business, expanding its relationship with CRISPR Therapeutics (CSPR) and buying gene therapy company Exonics Therapeutics.Exonics is involved in developing a gene therapy for Duchenne's muscular dystrophy (DMD). DMD is the most common form of the disease. It afflicts about 1 in 3,500 males and is usually recognized between the ages of 3 and 6 years of age. By age 10, most patients are wheelchair bound.Creating a gene therapy to resolve this rare disease would be massive. And given VRTX's history with CF, it has a very good shot. * 7 U.S. Stocks to Buy With Limited Trade War Exposure It's a relative outperformer in the big cap biotech space -- it sports a $43 billion market cap -- and is still a good value. Recro Pharma (REPH)Recro Pharma Inc (NASDAQ:REPH) is a small cap -- $206 million market cap -- that was launched in 2007. Its focus is on non-opioid, non-addictive pain and analgesics.It focuses its efforts on products for hospitals and ambulatory care facilities and works with generics to develop more effective delivery systems and more targeted markets.For example, its top-performing drug is meloxicam, an analgesic for post-operative pain that is administered intravenously. It also has an intranasal formulation of dexmedetomidine (Dex) for post-operative pain. Its third pipeline drug is fadolmidine and is similar to Dex but doesn't cross the blood-brain barrier.The stock is up 31% year to date and up 75% for the past 12 months. There's a good chance that its drugs could be fast-tracked considering the opioid crisis, which would get them to market even faster. Arrowhead Pharmaceuticals Corp (ARWR)Arrowhead Pharmaceuticals Corp (NASDAQ:ARWR) is a gene therapy biotech with a twist. Instead of using modified genes to eradicate a disease, it silences genes that are causing problems.Either way, this is a very hot sector and ARWR is one of the shining stars in the biotech heaven. It has a $2 billion market cap and has been around since 1989, which is means it has been through two or three waves of biotech booms and busts.The stock is on fire right now, up 108% year to date and 134% in the past year. Part of that is the news last October is signed a deal to license one of its drugs that targets hepatitis B to Janssen Pharmaceuticals. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 It's pricey, but it has a lot of big new ahead of it. Veracyte (VCYT)Veracyte Inc (NASDAQ:VCYT) is also on the genetic side of the biotech sector. But it doesn't develop novel drugs, it produces genetic testing for various types of diseases.This is another new sector that is growing quickly because of the processing power now available to sequence genes and see how they tick.Right now, VCYT has genetic tests for thyroid cancer, lung cancer and a lung disease called idiopathic pulmonary fibrosis. The latter has been very hard to test for in the past, so VCYT testing is a big step forward.With a $1 billion market cap, VCYT is establishing a name for itself and already has products in the market, which is a very attractive business model compared to drug companies that will spend years and billions of dollars hoping a drug will get to the marketplace.Up and staggering 214% in the past year and 121% year to date, VCYT is just getting started. And could be a serious takeover candidate. Affimed (AFMD)Affimed NV (NASDAQ:AFMD) is a Germany-based biotech that is focused on immunotherapy work. This line of work is built on the premise that you can find a way for each individual to help combat disease using their own immune system.This is highly complex and is in earlier stages than gene therapy but it has enormous potential, especially in treating various cancers.AFMD has a proprietary ROCK(R) platform for recognizing and attacking certain types of cancers. It cancelled phase 1 studies in October of AFM11 to focus on its innate cell engager AFM24.Immuno-oncology is more than just working with a patient's immune system. It also means individualized treatment solutions for each patient. That would be a massive shift in the way disease care is viewed. And it's getting very close. * 7 Dividend Stocks That Are Worth Your Money Also, being a German company, it would have access to the European markets as well as the U.S. markets due to its partnership with Genentech. But it's a small cap with some work to do, so be patient. Incyte Corp (INCY)Incyte Corp (NASDAQ:INCY) is a Delaware-based biotech that is another good-sized player with a market cap of $16 billion.It has one drug that has been in the marketplace for years now. JAKAFI is a treatment for a rare form of bone marrow cancer and it also has a use as a treatment for host-done issues with bone marrow transplants.When you have drugs for rare diseases you have less competition and you can also charge more since there is few to no competitors but the market is also very small. But this does help start generating revenue for a company that can then use that cash to develop more drugs without burning through cash waiting for a big breakthrough.INCY has cooperative agreements with Merck (MRK) and Bristol Myers Squibb (BMY) using a new drug to work with their immuno-oncology drugs that are already on the market. This could be a big opportunity since these two Big Pharma firms could help get this combination through regulatory hurdles.The stock is up 21% year to date but only 4% in the past year. Its partnerships with leading Big Pharma firms is a strategic play on broader industry exposure.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 7 Top-Rated Biotech Stocks to Invest In Today appeared first on InvestorPlace.

  • Glaxo Inks Genome Research Deal With University of California
    Zacks5 days ago

    Glaxo Inks Genome Research Deal With University of California

    Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.

  • 3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
    InvestorPlace5 days ago

    3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics

    It was a victory for stocks on Thursday, though not a decisive one. The 0.41% gain logged by the S&P 500 keeps it above some important technical support, but one rough day could still put the broad market into something of a tailspin.Walt Disney (NYSE:DIS) shares did more than their fair share of the heavy lifting, up 4.4% largely after Morgan Stanley predicted its planned streaming product, Disney+, would be even more successful than most investors have given it credit for. Restoration Hardware Holdings (NYSE:RH), also just called RH, logged one of the biggest wins on Thursday though, rallying more than 15% after topping its fiscal first quarter estimates.At the other end of the spectrum, Twitter (NYSE:TWTR) fell 3.1% after MoffettNathanson analyst Michael Nathanson suggested the recent strength made it a good time to take some profits.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNone make for great trading options headed into the weekend though. Rather, it's the stock charts of Nektar Therapeutics (NASDAQ:NKTR), Vertex Pharmaceuticals (NASDAQ:VRTX) and Symantec (NASDAQ:SYMC) that present themselves as the top prospects. Here's why. Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals is no stranger to big swings in both directions. In fact, big swings are the norm. These aren't just sizeable, trade-worthy movements though. They're actually pretty predictable in terms of size and scope. The turns are taking shape pretty much where they should, even if VRTX is incapable of moving anywhere in a straight line. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 The stock's back at a well-established technical floor now, suggesting a rebound move is nigh. This revisit of a familiar floor does look a little bit different though, in that the stock's struggled to push up and off of it. It may be a clue that the bears are just waiting to deal a proverbial death blow. Click to Enlarge • The range in question is plotted with white lines on both stock charts, tracing the major highs and lows going all the way back to 2017.• Bolstering the case for a bounce here is the fact that the stochastic indicator is into oversold territory. That's not a condition that's been allowed to last long for Vertex Pharmaceuticals, but…• …zooming out shows that VRTX has been hugging the floor in question since April. It should have rebounded by now. One or two rough days could break the support, perhaps unleashing a wave of pent-up selling. Nektar Therapeutics (NKTR)Nektar Therapeutics was beaten so badly last year that traders have been wary of stepping back into it now. But, to its credit, at least the bleeding has stopped. The few bulls still testing the waters have even established a technical floor since late last year.There's a much bigger method to the madness though. That is, the selling has been slowly but surely ground to a halt, and the would-be buyers are establishing a base from which to carry the stock higher again. While there's still much work to be done, that work is being done. Click to Enlarge • The floor in question is plotted in yellow on both stock charts, tagging all the key lows going back to late December.• Zooming out to the weekly chart we can see shares of NKTR have already started to poke through falling resistance lines.• The key to, and signal of, a fully established breakout thrust is the next move above the white 200-day moving average line at $40.86 and the weekly chart's Chaikin line moving back above the zero level. Symantec (SYMC)In late March Symantec was featured as a name that had been range-bound for several weeks, and of the effort to push above a well-established ceiling at the time failed, a retreat back to the lower boundary of that range was likely.SYMC did indeed punch through that ceiling, though it was a flawed break. With a gap left in the rearview mirror, shares started to peel back in May and eventually made their way back to the support portion of the range anyway. Since kissing that floor late last month though, the bulls appear to have regrouped and are ready to make the trip back to the ceiling again. Click to Enlarge • The range in question is between $17.50 and $23.60, marked with red and yellow lines on both stock charts.• The weekly chart also shows an oversold stochastic indicator, which more often than not does point where Symantec has moved to an unsustainable extreme.• Curiously, though shares have yet to make a solid upward move, the weekly chart's rising Chaikin line suggests there's a lot more buying interest than selling pressure in place right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics appeared first on InvestorPlace.

  • Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray
    American City Business Journals6 days ago

    Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray

    The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks7 days ago

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
    Motley Fool7 days ago

    5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

    New blockbusters could be on the way for five drugmakers.

  • CELG or VRTX: Which Is the Better Value Stock Right Now?
    Zacks8 days ago

    CELG or VRTX: Which Is the Better Value Stock Right Now?

    CELG vs. VRTX: Which Stock Is the Better Value Option?

  • Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy?
    Insider Monkey8 days ago

    Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy?

    Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • CRISPR Therapeutics Up on Collaboration Expansion by Vertex
    Zacks9 days ago

    CRISPR Therapeutics Up on Collaboration Expansion by Vertex

    CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for VRTX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding VRTX totaled $13.82 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 3 Healthcare Stocks I'd Buy Right Now
    Motley Fool10 days ago

    3 Healthcare Stocks I'd Buy Right Now

    Illumina, Teladoc Health, and Vertex Pharmaceuticals enjoy strong competitive advantages and great growth opportunities.

  • Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
    Motley Fool10 days ago

    Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

    Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.

  • Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing
    Investor's Business Daily12 days ago

    Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing

    Vertex Pharmaceuticals is betting on gene-editing treatments with the acquisition of private biotech company Exonics Therapeutics and a deeper collaboration with Crispr Therapeutics.

  • Benzinga12 days ago

    Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion

    Gene editing is an emerging field, and  Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )  is plunging headlong into it with two deals announced Thursday after the market close.  Expanded Collaboration, Licensing ...

  • Barrons.com12 days ago

    Vertex Pharmaceuticals Bets on Gene Therapy With New Acquisition

    Analysts are cheering a new acquisition by Vertex Pharmaceuticals to jump start its gene-therapy program.

  • Vertex Expands Collaboration With CRISPR, Acquires Exonics
    Zacks12 days ago

    Vertex Expands Collaboration With CRISPR, Acquires Exonics

    Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.

  • Benzinga12 days ago

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Vertex enters Duchenne field with $245M buy of Exonics
    American City Business Journals13 days ago

    Vertex enters Duchenne field with $245M buy of Exonics

    Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.

  • Business Wire13 days ago

    Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.

  • The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

  • 5 Biotech Stocks to Buy Right Now
    Zacks15 days ago

    5 Biotech Stocks to Buy Right Now

    here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.

  • Business Wire15 days ago

    Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42nd European Cystic Fibrosis Conference, taking place June 5-8, 2019 in Liverpool, UK. These abstracts include data being presented from the ongoing Phase 3 ARRIVAL study of the pharmacokinetics (PK) and safety of KALYDECO® (ivacaftor) in a cohort of patients 6 to

  • Watertown biotech Lyndra snags longtime Vertex exec as CEO
    American City Business Journals16 days ago

    Watertown biotech Lyndra snags longtime Vertex exec as CEO

    Vertex’s current senior vice president of pharmaceutical and preclinical sciences, Patricia Hurter, will become chief executive at Lyndra on Sept. 3, according to the startup.

  • Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally
    Yahoo Finance Video12 days ago

    Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally

    Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.